Integrated Analytical System for Clinical Single-Cell Analysis

Peterson, Hannah M.; Chin, Lip Ket; Iwamoto, Yoshiko; Oh, Juhyun; Carlson, Jonathan C. T.; Lee, Hakho; Im, Hyungsoon; Weissleder, Ralph

Published in:
Advanced Science

Published: 15/07/2022

Document Version:
Final Published version, also known as Publisher’s PDF, Publisher’s Final version or Version of Record

License:
CC BY

Publication record in CityU Scholars:
Go to record

Published version (DOI):
10.1002/advs.202200415

Publication details:
Peterson, H. M., Chin, L. K., Iwamoto, Y., Oh, J., Carlson, J. C. T., Lee, H., Im, H., & Weissleder, R. (2022). Integrated Analytical System for Clinical Single-Cell Analysis. Advanced Science, 9(20), Article 2200415. https://doi.org/10.1002/advs.202200415

Citing this paper
Please note that where the full-text provided on CityU Scholars is the Post-print version (also known as Accepted Author Manuscript, Peer-reviewed or Author Final version), it may differ from the Final Published version. When citing, ensure that you check and use the publisher's definitive version for pagination and other details.

General rights
Copyright for the publications made accessible via the CityU Scholars portal is retained by the author(s) and/or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights. Users may not further distribute the material or use it for any profit-making activity or commercial gain.

Publisher permission
Permission for previously published items are in accordance with publisher’s copyright policies sourced from the SHERPA RoMEO database. Links to full text versions (either Published or Post-print) are only available if corresponding publishers allow open access.

Take down policy
Contact lbscholars@cityu.edu.hk if you believe that this document breaches copyright and provide us with details. We will remove access to the work immediately and investigate your claim.

Download date: 12/10/2024
Integrated Analytical System for Clinical Single-Cell Analysis

Hannah M. Peterson, Lip Ket Chin, Yoshi Iwamoto, Juhyun Oh, Jonathan C. T. Carlson, Hakho Lee, Hyungsoon Im, and Ralph Weissleder*

High-dimensional analyses of cancers can potentially be used to better define cancer subtypes, analyze the complex tumor microenvironment, and perform cancer cell pathway analyses for drug trials. Unfortunately, integrated systems that allow such analyses in serial fine needle aspirates within a day or at point-of-care currently do not exist. To achieve this, an integrated immunofluorescence single-cell analyzer (i2SCAN) for deep profiling of directly harvested cells is developed. By combining a novel cellular imaging system, highly cyclable bioorthogonal FAST antibody panels, and integrated computational analysis, it is shown that same-day analysis is possible in thousands of harvested cells. It is demonstrated that the i2SCAN approach allows comprehensive analysis of breast cancer samples obtained by fine needle aspiration or core tissues. The method is a rapid, robust, and low-cost solution to high-dimensional analysis of scant clinical specimens.

1. Introduction

Phenotypic classification of tumors is essential in clinical decision making, unraveling the complexity of human tumor microenvironment and determining the presence of drug-able targets. Clinically, this is currently achieved by obtaining tumor tissue through surgical excision or image-guided biopsies with subsequent immunohistochemical staining to yield data on a relatively small subset of markers per sample. Rapid advances in molecular oncology, however, have raised unique unmet needs: i) establishing higher-dimensional biomarker panels rather than relying on a few chosen biomarkers, ii) performing analysis at higher throughput in an automated fashion and in short periods of time (same day), iii) substituting invasive core biopsies with lower morbidity fine needle aspirates (FNAs), and iv) performing temporal analyses of the tumor microenvironment in patients undergoing treatments. If possible, such an approach could have significant impacts on patient care in medical centers and point-of-care settings across the globe.

Unfortunately, widely used conventional immunohistochemistry approaches are associated with technical limitations such as low throughput, requirements for multiple sections to process different biomarkers, frequent paucity of cytological sample materials resulting in nondiagnostic cases and interobserver variability.[1]

A number of highly multiplexed immunofluorescence techniques have emerged,[1–5] but many of them face similar constraints of long turn-around times, computational complexity, high cost, and incompatibility with cytology specimens due to harsh cycling conditions. As a result, the methods are primarily used as research tools to study cell composition, cellular function, and cell–cell interactions. Similarly, low-cost and integrated microscopes have been described,[6] but they have yet to be adapted for multiplexed fluorescence analysis of clinical samples.

We have been addressing the above needs by developing automated image cytometry systems[7] that can be used in remote settings where the access to resources and expert help is restricted.[8] FNAs, yielding cells rather than tissue, are ideally suited in such environments given the very low morbidity, simplicity of sample acquisition, and chromogenic staining. Up to now, such samples still required expert cytological interpretation, and immunostaining may not be available in remote locations, especially for scant samples. We have been thus interested in developing more advanced automated systems to analyze both FNA and tissue core samples, i.e., the clinically most common sample types. To further improve the diagnostic accuracy and utility, we were also interested in combining the device with ultrafast multiplexing capabilities (FAST), so that cyclic imaging could be performed within a few hours rather than days to weeks. Recent advances in chemistry[9–12] are beginning to enable...
such workflows,[13] but have not been implemented for breast cancer.

Here, we report an inexpensive, robust, multichannel single-cell imaging system (i2SCAN: integrated immunofluorescence single-cell analyzer) with integrated analysis. We combined i2SCAN with FAST cyclic imaging to measure >12 biomarkers in scant cells and tissues. We implemented such a system and workflow through iterative improvements of design and based on practical insights from field testing. The design requirements included no moving filters to speed up acquisition and durability, integrated operation to minimize manual intervention, and computational analyses yielding clinically actionable results. Using breast cancer as a model system, we show that i2SCAN overcomes many of the previous technical hurdles and expands profiling capabilities in the clinic.

2. Results

2.1. i2SCAN Enables Rapid Acquisition of Whole Slide Datasets

Three major impediments exist to enable accurate and same-day molecular diagnosis of solid cancers: i) a considerable fraction of cytological specimens processed by conventional means are nondiagnostic,[14,15] ii) highly trained specialists, who are needed to review samples, are often lacking in low- and middle-income countries and point-of-care settings,[16] and iii) the sample processing is complex and long, involving tissue embedding, sectioning, and sequential re-staining with different antibodies. Conversely, it has been shown that deep molecular profiling of cells obtained by FNA enables molecular diagnoses[11,17] but such technology has not yet been adapted to routine clinical workflows or in remote settings. We thus set out to develop such a workflow encompassing i) a low-cost integrated device; ii) unique reagents and staining protocols for rapid deep multiplexing of cellular samples; and iii) computational analyses to facilitate interpretation (Figure 1). Such a workflow could enhance clinical practice, decrease the number of nondiagnostic samples, and minimize the time delay to the initiation of therapy (Figure S1, Supporting Information).

2.2. i2SCAN System Design and Characterization

Figure 2 and Figure S2 in the Supporting Information summarize key components of the standalone i2SCAN system. The optics design addressed some of the limitations of a previous analytical system[8,18] which enabled only three-color imaging without the ability to perform deeper multiplexing required for accurate diagnoses. We purposely designed a new system without a moving excitation and emission filter turret. This approach improved durability, minimized service needs, decreased system cost, and sped up image acquisition. We used a five-channel penta filter and configured a lateral illumination light path (Figure 2A). Instead of expensive lasers or multispectral light sources, we used multiple light-emitting diodes (LEDs); each LED was cooled by a heat sink to stabilize light output. The image was acquired by a color CMOS (complementary metal oxide semiconductor) imager which was mounted on a linear actuator for auto-focusing. We chose a color imager over a monochromatic one to perform spectral fingerprinting as well as compensate for channel bleed through, allowing us to profile single cells in six colors. The overall system operation was controlled by an embedded microcontroller (Figure 2B) that synchronized LED on-offs with image acquisition. Images were acquired with only one LED turned on at any given time. Figure 2C details the computational aspects of image acquisition and analysis. A standalone software package was developed with a user-friendly interface to perform calibration, auto-focusing, image capture, and subsequent analysis (see below and Figure S3, Supporting Information).

2.3. Characterization of i2SCAN Optics

Figure 3 shows i2SCAN spectral characteristics and performance of image acquisition (see Figure S4 in the Supporting Information for additional detail). The system had a white LED for bright-field imaging and five color LEDs for fluorescent imaging (L385nm, L470nm, L567nm, L627nm, L720nm). Each color LED was coupled with an in-line bandpass filter to narrow the excitation wavelength (Figure 3A and Figure S4, Supporting Information). This set-up allowed us to use commonly used...
Figure 2. i2SCAN imaging system. A) 3D rendering showing the lateral light path of an LED to illuminate the sample in such a way that the imaging sensor is not flooded. LEDs are mounted on heat sinks to stabilize output power. A total of six LEDs are used. A linear actuator is used for auto-focusing. B) Schematic diagram of a custom-designed microcontroller for sequential illumination of the sample through each LED and synchronization with the image sensor. C) A standalone software package was developed with a user-friendly interface to: i) perform daily calibration of the system; ii) control the LEDs, linear actuator, and imaging sensor; iii) perform auto-focusing and image capturing; iv) perform image analysis for cell-nucleus segmentation and classification.

Figure 3. Spectral characteristics. A) Summary of spectral characteristics of i) the five LEDs with excitation filters (to limit broader LED spectra), ii) fluorochrome excitation, and iii) fluorochrome emission with a penta emission filter. B) SNR of beads stained with DAPI (blue), AF488 (green), AF555 (yellow), AF647 (red), and CF750 (brown). Note the uniformly high SNR across LED/filter/fluorochrome combinations. C) The CV of cells stained by six different fluorochromes. D) Repeat measurements of light output through different LEDs. Note the narrow CV.
fluorochromes such as DAPI (4',6-diamidino-2-phenylindole), BV605, AF488, AF555, AF647, and CF750. The penta filter aligned with the emission wavelengths of each of these fluorochromes.

We first tested the system with fluorescent beads and fluorochrome-stained cells. To rule out the interference from bleed through, we used beads and cells of a single fluorescent color. The bead signal-to-noise ratio (SNR) was high and uniform, reaching >200 for some of the indocyanine fluorochromes (Figure 3B). We also performed similar experiments with stained cells and directly compared SNR values between the i2SCAN system and a commercial microscope equipped with LED light sources and multibandpass filters. Across all fluorescent channels, i2SCAN displayed higher SNR than the commercial system (L470/AF488: i2SCAN 86.3 vs microscope 65.6; L567/AF555: i2SCAN 73.0 vs microscope 46.0; L627/AF647: i2SCAN 214.5 vs microscope 168.5; L720/CF750: i2SCAN 7.9 vs microscope 3.9). This can be attributed to the side-illumination scheme in i2SCAN, which minimized the entrance of stray excitation light into an imager. The coefficient of variance (CV) for stained cells in an entire field of view was narrow with mean values around 4% (Figure 3C). Finally, we monitored the optical output through each LED and confirmed that it was within specification over prolonged use with the CV less than 0.5% (Figure 3D).

2.4. Automated RGB Fingerprinting Yields Unmixed, High-Quality Image Analysis

Fluorescence imaging of cells stained with multiple fluorochromes invariably leads to fluorescence bleed through into adjacent channels given the broad emission spectra of organic rhodamine/cyanine dyes. To remove such artifacts (beyond the use of filters and lateral illumination) in i2SCAN images, we developed an RGB fingerprinting method by analyzing pixel RGB outputs of each fluorochrome and compensated for bleed through signals. Figure 4A overlaps the emission spectral windows of the penta filter with the relative sensitivity of RGB sensors in the i2SCAN imager. The RGB sensors create a unique signature for each fluorochrome that is used for spectral unmixing. Figure 4B details the experimental measurements of RGB signals for a given LED and fluorochrome. The highest bleed through was observed with L470/AF488 (into the DAPI channel), L385/BV605 (into the AF555 channel), and with L720/CF750 (into the AF647 and DAPI channels). Given the different ratios on R, G, and B channels, we used this information to correct images for bleed through signals.

Figure 4A shows raw and corrected cell images stained with different fluorochromes and illuminated with different LEDs (top). Without correction, there is up to 60% of bleed through into adjacent channels. After fingerprint correction (bottom), the signals are clearly separated.
Figure 5. Automated single-cell analysis. To determine whether single cells could be stained with FAST probes and analyzed through fingerprinting, we examined BT474 (HER2+/ER+/PR+) and MD-MB-231 cells (triple negative breast cancer). A) Representative examples of BT474 stained for the markers shown (left) and automated analysis of biomarker expression after fingerprint correction (right). Note the high levels of HER2 and ER/PR. B) Examples of triple-negative MD-MB-231 cells stained for the same markers and showing low levels of HER2 and ER/PR, but positive signals from cancer markers (EpCAM, MUC1). C) Correlation between i2SCAN measurements and flow cytometry. Note the good correlation (Pearson r = 0.90). D) i2SCAN analysis of tumor cell/PBMC mixture displayed CD45 versus QUAD (HER2/EpCAM/MUC1/EGFR). Note the clean separation (Raw images in panels A and B are brightness and contrast adjusted).

2.5. Multiplexed Analysis in Single-Cell Suspensions

Tumor cells can be clinically harvested from palpable mass lesions by image-guided FNAs. This minimally invasive procedure uses 22–25G needles to obtain single cells or cell clusters for subsequent analysis. An average of ≈2 mg of material or ≈1000 cells (range 100–5000) can be obtained from a single needle pass. Because the materials can be of such low cellularity, the rate of nondiagnostic specimens can be as high as 30%,[21,22] even with expert sampling and processing. To determine whether i2SCAN could be used for multiplexed analyses of single cells, we first processed cell lines whose marker presence is established and can be independently validated by flow cytometry.

Figure 5 shows a representative example of triple-positive (HER2+/ER+/PR+) BT474 breast cancer cells, stained and analyzed by i2SCAN. Virtually all cells were positive for HER2 (human epidermal growth factor receptor 2), ER (estrogen receptor), PR (progesterone receptor), EGFR (epidermal growth factor receptor), and EpCAM (epithelial cell adhesion molecule). In contrast, the triple negative (HER2-/ER-/PR-) MDA MB231 cells showed negligible fluorescent signal for HER2, ER, and PR, but were positive for cancer markers (EGFR not shown) and MUC1 and EpCam. Figure 5C shows that there was good correlation between i2SCAN analysis and flow cytometry (Pearson r = 0.90). In an analysis of a tumor cell/immune cell mixture, a clean separation between tumor (HER2+/EpCAM+/MUC1+/EGFR+) and immune cells (CD45+) was observed (Figure 5D). Once the above approaches were validated in cell lines, we proceeded to processing primary human samples (Table 1). Staining was performed with the FAST cycling method (Figure
### Table 2. Antibodies for flow and direct single cell staining.

| Marker | Tumor subtype/cell type | Vendor       | Cat #   | Clone | Host   | Cell line |
|--------|-------------------------|--------------|---------|-------|--------|-----------|
| 1      | EpCAM                   | Biolegend    | 324202  | 9C4   | Mouse  | BT474     |
| 2      | EGFR                    | Abcam        | ab30    | EGFR1 | Mouse  | MDA-MB-231|
| 3      | HER2                    | BioRad       | MCA1788 | ICR5  | Rat    | BT474, HCC-1954|
| 4      | HER2                    | Biolegend    | 324402  | 24D2  | Mouse  | BT474     |
| 5      | ER (ESR1)               | CST          | 13258S  | D6R2W | Rabbit | BT474     |
| 6      | PR (PGR)                | CST          | 87575   | D8Q2I | Rabbit | BT474     |
| 7      | MUC1                    | Fitzgerald   | 10-M93A | 10-M93A | Mouse | MDA-MB-231|
| 8      | CD45                    | CST          | 13917   | D9M81 | Rabbit | PBMC      |
| 9      | IgG Control             | CST          | 3900    | DA1E  | Rabbit | N/A       |
| 10     | IgG Control             | Biolegend    | 400501  | RTK2758 | Rat | N/A        |
| 11     | IgG Control             | Biolegend    | 400102  | MOPC-21 | Mouse | N/A       |
| 12     | IgG Control             | Biolegend    | 400302  | MPC-11 | Mouse | N/A       |

### Table 3. FAST antibodies for staining of paraffin-embedded tissue sections (FFPE).

| Marker | Tumor subtype/cell type | Vendor       | Cat #   | Clone | Host | Fluor | Cell line |
|--------|-------------------------|--------------|---------|-------|------|-------|-----------|
| 1      | EpCAM                   | R&D Systems  | AF960   | Polyclonal | Goat | AF488 | A431      |
| 2      | EGFR                    | R&D Systems  | AF231   | Polyclonal | Goat | AF488 | A431      |
| 3      | HER2                    | CST          | 453328C | 29D8  | Rabbit | AF488 | BT474     |
| 4      | ER (ESR1)               | Abcam        | ab282199 | SP1   | Rabbit | AF555 | MCF 7     |
| 5      | PR (PGR)                | R&D Systems  | AF5415  | Polyclonal | Sheep | AF647 | T-47D     |
| 6      | Ki67                    | Abcam        | ab15580 | Polyclonal | Rabbit | AF647 | A431      |
| 7      | CK7                     | BioLegend    | 601602  | W16155A | Rat | AF647 | RT4       |
| 8      | MUC1                    | BioLegend    | 355602  | 16A   | Mouse  | CF750 | U-2 OS    |
| 9      | TROP2                   | Abcam        | ab214488 | EPR20043 | Rabbit | AF647 | BT474     |
| 10     | GATA3                   | CST          | 5852BF  | D13C9 | Rabbit | AF555 | A431      |
| 11     | CD45                    | CST          | 479375F | D9M8I | Rabbit | AF555 | PBMC      |
| 12     | CD68                    | CST          | 916104  | KP1   | Mouse  | AF647 | PBMC      |
| 13     | CD31                    | CST          | 858735F | 89C2  | Mouse  | AF488 | HUVEC     |
| 14     | CD34                    | Bio-Rad      | MCA547G | QBEND/10 | Mouse | BV605 | HUVEC     |
| 15     | CD8                     | CST          | 85336BF | DBA8Y | Rabbit | AF647 | PBMC      |
| 16     | SMA                     | Thermo Fisher| 14-9760-82 | 1A4    | Mouse  | AF555 | A431      |

### S6, Supporting Information), which is compatible with cellular harvests.

### 2.6. Multifactorial Analysis of Tissue Sections Provides High Accuracy

We next proceeded to analyze tissue samples such as those obtained during surgical resection or core biopsies. Because tissues are embedded in paraffin and sectioned, additional optimization and validation steps were necessary for the FAST-FFPE (formalin-fixed paraffin-embedded) cycling technique (Figure S7, Supporting Information). Compared to images acquired with a conventional microscope taken at a similar magnification (10x objective, 1728 × 1728 pixels), the i2SCAN has a larger field of view (2448 × 2048 pixels) with a similar pixel resolution (≈0.6 μm pixel⁻¹). For additional comparison, a commercial whole slide scanner had a large field of view (51840 × 21760 pixels) and a resolution of 0.5 μm pixel⁻¹. As shown in Figure S7 in the Supporting Information, the image quality is comparable among the three methods. Based on iterative analyses, we changed some of the antibodies for better performance in tissues (Tables 2–4). Once optimized, we proceeded to analyze tissue samples from patients. Figure 6 provides a summary of the representative raw images from a panel of 14 biomarkers imaged in breast cancer specimens.

### Table 4. Labeling kits.

| Marker                        | Vendor       | Cat #   |
|-------------------------------|--------------|---------|
| 1 Mix-n Stain CF750 Antibody  | Biotium      | 92284   |
| 2 Brilliant Violet 605 Goat anti-mouse IgG (clone: Polyclonal) | BioLegend | 405327 |

Adv. Sci. 2022, 9, 2200415 (6 of 12) © 2022 The Authors. Advanced Science published by Wiley-VCH GmbH
Setting appropriate thresholds for biomarker analysis is essential in performing cell-by-cell-based analyses. We determined the thresholds for marker positivity by single-cell analysis and correlation to daughter sections processed for immunohistochemistry, similarly as done in other immunological validation studies. Based on the threshold values, i2SCAN was then used to analyze tissue for marker presence, degree of positivity, and spatial arrangement. Figure 7 summarizes representative examples of thresholds for key therapeutic targets (HER2, ER, PR, TROP2, CD8).

We next determined whether the i2SCAN method could be used to analyze a cohort of breast cancer tissues. FFPE samples from 19 patients were obtained and processed via FAST staining and i2SCAN automated analysis. In a first step, we computationally separated host from tumor cells at the single-cell level. Figure 8A shows a representative example of such analysis where host cells are clearly separated from tumor cells in fibrous septa. Tumor cell analysis was subsequently performed to determine the expression level of each protein of interest in a given cell. This allowed us to display HER2, ER, or multiparameter cellular maps of the tumor environment. These analyses also allowed patient (Figure 8B) and cohort wide (Figure 8C,D) analyses. In summary, the above experiments demonstrate that the i2SCAN approach allows comprehensive analysis of breast cancer samples obtained by fine needle aspiration or core tissue sections.

### 3. Discussion

In this study, we describe i2SCAN, an integrated combined workflow enabling the rapid analysis of co-expression of dozens of proteins in thousands of single cells. This is important because single-cell protein analysis has not been widely adapted for clinical use for a number of reasons. Although a considerable number of different cycling technologies have been published for FFPE sections, these tools are mostly used in research given their long staining and destaining times, high cost, and lack of reimbursement. Furthermore, the issue of adapting high-dimensional analysis to scant cytopathological samples has generally not been solved. The latter is particularly attractive in a clinical setting because it would allow for simplified sampling with much smaller needles, lower morbidity and complication rates, better patient acceptance, thus obviating the need for anesthesia and monitored deep sedation. i2SCAN was designed to enable such analyses on scant cellular samples (10^2–10^4 cells) and may thus find particular use in serial immune cell profiling, global health applications, or whenever lesions are too small or central (e.g., endoscopy, fluid sampling) for core biopsies or resection.

i2SCAN integrates three technical advances into a single workflow. First, it is based on a compact, multichannel imaging system equipped with a lateral light illumination setup, a penta filter, and an RGB camera. The device has no moving filter parts, uses LEDs rather than lasers, and is thus fast and economical. Second,
Figure 7. i2SCAN of biomarkers in FFPE sections. Tissue microarrays representing 24 patients with pathology proven breast cancer and variable expression levels of HER2, ER, and PR were analyzed by i2SCAN. Shown are representative examples for biomarker positive and negative cases. A) Synthetic images of representative cases positive for the biomarker shown and which was corroborated with IHC, FISH, and other testing. B) Synthetic images of representative cases confirmed negative for the biomarker shown. C) Summary plots of signal in segmented tumor cells. The threshold for a given marker was determined in representative samples (with and without controls).

Figure 8. Analysis of cellular biomarkers in patient cohort. A) Synthetic images derived from FFPE tissue section. Note the exclusive separation of tumor and host cells and the ability to analyze individual cells for markers. Top right: Mosaic of individual cancer cells that express multiple markers (red; positive for HER2, ER, PR, and/or Ki67), Ki67 only (yellow), HER2 only (purple), ER/PR only (green), or no HER2/ER/PR/Ki67 (orange). B) Summary of biomarker expression in one patient sample. A total of 14 markers were analyzed. C) Summary of HER2 expression across patient cohort (n = 19 patients). D) Summary of ER expression across patient cohort (n = 19 patients).
have directly programmed all of this into the linker and developed various iterations of this design. This enables immediate and complete quenching of the fluorescence once an image is acquired and subsequent cycles of staining can be performed rapidly. In the current study, we used quench times of 15 min for cells and 45 min for tissue sections. However, in other studies and using higher concentrations of Tz, we have used quench times as short as 10 min. Third, i2SCAN uses automated image analysis for spectral deconvolution and thresholding algorithms to compare expression data from single cells. Combined, the information can be used for clinical decision making, immunologic phenotyping, pathway analysis, or other relevant questions in human biology.

The depth of phenotyping is primarily limited by the antibody panel used. Here, we used a panel of 14 antibodies relevant to the differential diagnosis of breast lesions. Additional FAST panels are being developed for immune cell profiling of the tumor microenvironment and live-cell imaging, while other panels have been developed for breast cancer pathway analysis. Additional panels are simple to add as long as high-quality antibodies are available. Antibody modification with FAST reagents is straightforward and does not require deep chemical expertise. In the current study, we focused on five different fluorochrome channels and utilized the sixth channel (DAPI) to image all cellular nuclei across every cycle. This facilitated cell segmentation and registration, as the DAPI channel in each cycle served as a spatial alignment map. While we used a total of four cycles in the current study, we have expanded the concept to over 15 cycles in experimental samples. It is further possible to expand the diagnostic information content by combining markers to identify new unique cell populations. For example, a 20 marker panel can be used in a combinatorial fashion by combining multiple markers to identify hundreds of distinct cell populations.

A key in the analytical pipeline is stringent quality control of antibodies (signal comparison to IgG control) and the use of quality control measures routinely employed in clinical immunofluorescence assays and flow cytometry designs. These include avoiding fluorochromes with spectral overlap, low quantum-yield fluorochromes, environmentally sensitive fluorochromes, or antibodies with high background binding. It also includes proper signal compensation across channels, appropriate scaling and referencing to another gold standard (immunohistochemistry, proteomics), and judicious combinations of antibody panels, i.e., pairing bright fluorophores with dimly expressed markers. i2SCAN is compatible with use of fluorescent proteins, commercially available prelabeled antibodies, other labeling methods as well as the FAST cycling technology used here. Our results show that the RGB fingerprinting enabled accurate compensation for fluorescence bleed through between channels. RGB fingerprinting was possible in part by using a new color CMOS imager that matches the sensitivity of older monochromatic ones. We furthermore show that i2SCAN yields accurate information on marker expression on a single-cell basis. However, care has to be taken to translate such information into actionable clinical diagnoses. Currently, such information is limited, and prospective trials will have to be conducted to determine the accuracy of new approaches. The current approach and previous iterations can potentially enable clinical diagnoses with $10^2$-$10^4$ cells. This is much lower than the $10^7$-$10^8$ cells required for traditional analyses. Irrespective of the findings and limitations, patterns of biomarkers identified in samples should always be validated by additional data.

Given the wealth of information provided by the i2SCAN workflow and its affordability, we anticipate that it could become a useful adjunct to diagnostics in the wider community.

4. Experimental Section

i2SCAN System: Six LEDs were used for the imaging in brightfield and five fluorescence channels (six fluorochromes): a BF LED (Adafruit, 1622) for brightfield, an L385 (LuxeonStar, SZ-05-U3) with a low-pass filter (400 nm, Edmund Optics, 84–689) for DAPI and BV605, an L470 (LuxeonStar, SZ-05-H3) with a 10 nm bandpass filter (470 nm central wavelength, Edmund Optics, 65–083) for AF488, an LS67 (LuxeonStar, SZ-05-H9) with a 25 nm bandpass filter (550 nm central wavelength, Edmund Optics, 86–643) for AF555 or AF594, an L627 (LuxeonStar, Sz-05-H6) with a 10 nm bandpass filter (640 nm central wavelength, Edmund Optics, 65–107) for AF647, an L720 (LuxeonStar, SP-03-D4) with a 25 nm bandpass filter (750 nm central wavelength, Edmund Optics, 86–647) for CF750. The L385 LED was fixed directly on the slide holder with a custom-designed heat sink. The rest of LEDs were fixed on a custom-designed holder; each LED module consisted of a focusing lens, an excitation filter, the LED, and a heat sink. The optical imaging module was consisted of an objective lens (Nikon, 20x, 0.70 NA), a pentafilter (Semrock, FF01-432/515/595/681/809-25), and a 2448×2048 5-MP color imaging sensor (TheImagingSource, DFM 37UX250-ML containing a 2/3 inch Sony CMOS Pregius sensor, IMX250). A linear actuator (Dings’ Motion USA, Nema 8 Kaptive) was used to change the position of the imaging sensor for auto-focusing (Figure S8, Supporting Information). The optomechanical components were either purchased from Thorlabs or designed in-house and custom-built through Xometry. A micro-controller (Arduino, Arduino Nano) was used to control a hall-effect sensor (Littelfuse, 55140–3H-02-A), the linear actuator and the LEDs, automatic focusing, and image acquisition, respectively. The CAD drawings for the custom-designed slider holder and heat sinks are freely available for academic researchers at https://csb.mgh.harvard.edu/bme_software.

User Interface: The control software with a graphical user interface was written in Visual Basic (Visual Studio 2019) and is freely available for academic researchers at https://csb.mgh.harvard.edu/bme_software. Daily calibration, auto-focusing, sample imaging, image analysis, and report generation were all built into the software to facilitate end-user operation. Daily calibration was performed using AccuCheckTM ERF reference particles (Thermo Fisher Scientific, A55950) to ensure that the detected fluorescence signals on respective channels were within the thresholds. The protocol for sample imaging was as follows: Sample slide was mounted on a holder and inserted into the system. The holder positioning was detected by the Hall sensor (Littelfuse, 55140–3H-02-A). Auto-focusing was performed first through a coarse focal search in the DAPI channel; and then a focus quality assessment (FQA) was automatically performed by analyzing the focus quality within seven focal planes. To determine the best focus plane (Figure S8, Supporting Information), the imager was displaced in the axial direction by the linear actuator with a step size of 150 μm. A reference-free FQA called FQPath was used to quantify the focus plane quality. Once the best focal plane was determined, the image capturing process started by switching on each LED for 5 s to stabilize its intensity, followed by image capture based on pre-set imaging conditions (including exposure time and camera gain). The image capturing process was completed within 1 min. Image analysis was then performed including image alignment, cell-nucleus segmentation, fingerprint analysis, and classification. The details are presented in the later section. The analysis report was generated. For daily calibration operation and focus analysis, Matlab

Adv. Sci. 2022, 9, 2200415

2200415 (9 of 12) © 2022 The Authors. Advanced Science published by Wiley-VCH GmbH
dynamic-link libraries were leveraged and integrated into the Visual Studio platform. Image analysis was done in Python and integrated through the Python extension.

Cell Culture: A panel of breast cancer cell lines with different expression of triple markers (ER, PR, HER2) was used for assay validation: MCF-7, BT474, HCC1954, and MDA-MB-231. All cell lines were purchased from the American Type Culture Collection (ATCC, Manassas, VA, USA). Human breast cancer cell lines MCF-7 and MDA-MB-231 were maintained in Dulbecco’s modified Eagle’s medium (DMEM, Thermo Fisher Scientific, Waltham, MA, USA); BT474 and HCC1954 were maintained in RPMI 1640 (Thermo Fisher Scientific, Waltham, MA, USA). All media were supplemented with 10% fetal bovine serum (FBS, Bio-Techne Sales) and 1% penicillin-streptomycin (Thermo Fisher Scientific, Waltham, MA, USA) and cultured at 37°C with 5% CO2. All cell lines were routinely tested using MycoAlert mycoplasma detection kit (Lonza, Basel, Switzerland). Peripheral blood mononuclear cells (PBMCs) were obtained from Stemcell Technologies (Cambridge, MA, USA).

FAST Antibodies: FAST probes were built around a modular linker between fluorophores and antibodies with an embedded trans-cyclooctene (TCO) for clicking with a tetrazine-conjugated quencher. FAST probes were custom synthesized at large scale, stored as the carboxylic acids, and activated (TCO) for clicking with a tetrazine-conjugated quencher. FAST probes were then incubated with 10-6 M Tz-BHQ (<10 min) in PBS-bicarbonate buffer (pH 9) for quenching. Free Tz-BHQ was removed by three washes with PBS, and the cells were imaged again in the same fields of view to record quenched signal. The same staining, imaging, and quenching cycle was repeated until all of the target proteins were imaged.

Immunostaining and Quenching of Cells: Cells were fixed for 15 min with CytoRich Red (Thermo Fisher Scientific, Waltham, MA, USA) and permeabilized for 10 min with 10% BSA in PBS before imaging. After blocking with assay buffer supplemented with 2.5% BSA and 2.5% normal goat serum for 10 min, cells were stained with FAST-conjugated antibodies for 20 min at RT in the dark. Stained cells were washed with PBS three times to remove unbound antibodies before imaging. Following image acquisition, cells were briefly incubated with 10-6 m Tz-BHQ (<10 min) in PBS-bicarbonate buffer (pH 9) for quenching. Free Tz-BHQ was removed by three washes with PBS, and the cells were imaged again in the same fields of view to record quenched signal. The same staining, imaging, and quenching cycle was repeated until all of the target proteins were imaged.

Immunostaining and Quenching of FFPE Sections: Tissue sections were stained in similar fashion as described for cells. The paraffin-embedded sections (tissue microarrays from US Biobank, Rockville, MD, USA; Sigma-Aldrich, St. Louis, MO, USA; Stat Lab, McKinney, TX, USA; US Biomax, Rockville, MD, USA) were de-paraffinized and rehydrated. Heat-induced antigen retrieval was performed using Retrievagene A at pH 6 (BD Biosciences, Franklin Lakes, NJ) and the sections were permeabilized with 0.3% Triton X-100 (Sigma-Aldrich, St. Louis, MO, USA) in PBS for 10 min at RT. The tissue sections were blocked with intercyt (PBS) blocking buffer (Licor) at RT for 1 h and FAST conjugated antibodies diluted in inter-
son correlation coefficient quantifying the correlations (two-sided \(p\)-value with \(\alpha = 0.05\)). For image processing, quality control excluded segmented cells with more than 1 nucleus and a nuclear-to-cell size ratio greater than 1. To identify outliers, cells were normalized to the 10th percentile and the 99th percentile of the mean fluorescent intensity was used for analysis. Processed images were quench-subtracted and synthetic images showed cell averages or phenotypes.

Supporting Information

Supporting Information is available from the Wiley Online Library or from the author.

Acknowledgements

The authors thank Drs. Claudio Vinegoni, Katy Yang, and Cesar Castro for valuable advice during this project. The authors are grateful to Dr. Hannes Mikula (TU Wien, Austria) for providing TCO building blocks. Dr. Kilean Lucas developed the LUT for image fusions. Part of this work was funded by UH3CA202637 (R.W.), R01CA257623 (R.W.), R01GM138779 (H.I.), R21CA217662 (H.I.), R01CA229777 (H.L.), DOD-W81XWH1910194 (H.L.), U01CA233360 (H.L.), MGH Scholar Fund (H.L.), and T32CA079443 (H.M.P.).

Conflict of Interest

The authors declare no conflict of interest.

Author Contributions

H.M.P., L.K.C., H.L., and H.I. contributed equally to the manuscript. System design and assembly: L.K.C., H.L., H.I., R.W. Software: L.K.C., H.M.P. H.M.P., L.K.C., H.L., and H.I. contributed equally to the manuscript. Systems: H.M.P., L.K.C., H.L., and H.I. contributed equally to the manuscript. Systems: H.M.P., L.K.C., H.L., and H.I. contributed equally to the manuscript.

Data Availability Statement

The data that support the findings of this study are available from the corresponding author upon reasonable request.

Keywords

biopsy, cancer, deep profiling, diagnostic

Received: January 21, 2022
Revised: March 31, 2022
Published online: May 4, 2022

[1] W. C. C. Tan, S. N. Nerurkar, H. Y. Cai, H. H. M. Ng, D. Wu, Y. T. F. Wee, J. C. T. Lim, J. Yeong, T. K. H. Lim, Cancer Commun. 2020, 40, 135.
[2] H. W. Jackson, J. R. Fischer, V. R. T. Zanotelli, H. R. Ali, R. Mechera, S. D. Soyalsal, H. Moch, S. Muenst, Z. Varga, W. P. Weber, B. Bodenmiller, Nature 2020, 578, 615.
[3] S. Berry, N. A. Giraldo, B. F. Green, T. R. Cottrell, J. E. Stein, E. L. Engle, H. Xu, A. Ogurtsova, C. Roberts, D. Wang, P. Nguyen, Q. Zhu, S. Soto-Diaz, J. Loyola, I. B. Sander, P. F. Wong, S. Jessel, J. Doyle, D. Signer, R. Wilton, J. S. Roskes, M. Eminizer, S. Park, J. C. Sunshine, E. M. Jaffee, A. Baras, A. M. De Marzo, S. L. Topalian, H. Kluger, L. Cope, et al., Science 2021, 372, eaab2609.
[4] Y. Goltsiev, N. Samusik, J. Kennedy-Darling, S. Bhat, M. Hale, G. Vazquez, S. Black, G. P. Nolan, Cell 2018, 174, 968.
[5] G. J. Baker, J. L. Muhlich, S. K. Palaniappan, J. K. Moore, S. H. Davis, S. Santagata, P. K. Sorger, Cell Syst. 2020, 11, 272.
[6] J. W. P. Brown, A. Bauer, M. E. Polinovsky, A. Bhumkar, D. J. Hunter, K. Gaus, E. Sierecki, Y. Gambin, Nat. Commun. 2019, 10, 5662.
[7] H. Lee, R. Weissleder, Nat. Rev. Mater. 2020, 5, 409.
[8] J. Min, L. K. Chin, J. Oh, C. Landeros, C. Vinegoni, J. Lee, S. J. Lee, J. Y. Park, A. Q. Liu, C. M. Castro, H. Lee, H. Im, R. Weissleder, Sci. Transl. Med. 2020, 12, eaaz9746.
[9] J. Ko, J. Oh, M. S. Ahmed, J. C. T. Carlson, R. Weissleder, Angew. Chem., Int. Ed. Engl. 2020, 59, 6839.
[10] J. Oh, J. C. T. Carlson, C. Landeros, H. Lee, S. Ferguson, W. C. Faquin, J. R. Clark, J. M. Pittet, S. I. Pai, R. Weissleder, Clin. Cancer Res. 2021, 27, 4781.
[11] R. J. Giedt, D. Pathania, J. C. T. Carlson, P. J. McFarland, A. F. Del Castillo, D. Juric, R. Weissleder, Nat. Commun. 2018, 9, 4550.
[12] J. H. Choi, L. K. Chin, B. M. Woo, Y. Song, M. J. Seol, Y. Hong, A. Q. Liu, S. Jang, H. Ploegh, H. Im, D. Lee, ACS Appl. Mater. Interfaces 2021, 13, 22124.
[13] S. I. Pai, W. C. Faquin, P. M. Sadow, M. J. Pittet, R. Weissleder, Cancer Cytopathol. 2020, 128, 782.
[14] E. Blondiaux, M. Laurent, E. Audureau, S. Boudjemaa, C. Sileo, M. Lenoir, L. Dainese, C. Garé, A. Coulomb, H. Ducou Le Pointe, Pediatr. Radiol. 2016, 46, 372.
[15] J. P. Brito, M. R. Castro, D. S. Dean, V. Fatourechi, M. Stan, Endocrine 2015, 49, 745.
[16] B. A. Chabner, J. Efstathiou, S. Dryden-Peterson, Oncologist 2013, 18, 777.
[17] A. V. Ullal, V. Peterson, S. S. Agasti, S. Tsuang, D. Juric, C. M. Castro, R. Weissleder, Sci. Transl. Med. 2014, 6, 219ra9.
[18] J. Min, H. Im, M. Allen, P. J. McFarland, I. Degani, H. Yu, E. Normandin, D. Pathania, J. M. Patel, C. M. Castro, R. Weissleder, H. Lee, ACS Nano 2018, 12, 9081.
[19] R. Weissleder, V. Ntziachristos, Nat. Med. 2003, 9, 123.
[20] V. Ntziachristos, J. Ripoll, L. V. Wang, R. Weissleder, Nat. Biotechnol. 2005, 23, 313.
[21] H. Wiskell, V. Ekstrand, C. Wadström, G. Auer, Phys. Med. 2009, 25, 128.
[22] E. Łukasiewicz, A. Ziemiecka, W. Jakubowski, J. Vojinovic, M. Bogucievska, K. Dobruch-Sobczak, J. Ultrason. 2017, 17, 267.
[23] A. Cossarizza, H. D. Chang, A. Radbruch, A. Acs, D. Adam, S. Adamklages, W. W. Agace, N. Gathagge, M. Ahdix, D. A. Bremer, A. B. Barlow, K. Gaus, E. Sierecki, Y. Gambin, J. Engelman, D. Juric, R. Mueller, R. Weissleder, JCO Precis. Oncol. 2017, 1, 1.
[24] J. C. T. Carlson, H. Mikula, R. Weissleder, J. Am. Chem. Soc. 2018, 140, 3603.
[25] R. Rashid, Y. A. Chen, J. Hofer, J. L. Muhlich, J. R. Lin, R. Krueger, H. Pfister, R. Mitchell, S. Santagata, P. K. Sorger, Nat. Biomed. Eng. 2021.
[26] N. E. Frenk, L. Spring, A. Muzikansky, H. V. Vadvala, J. M. Gurski Jr, L. E. Henderson, M. Mino-Kenudson, A. Ly, A. Bardia, D. Finkelstein, J. Engelman, D. Juric, R. P. Mueller, R. Weissleder, JCO Precis. Oncol. 2020, 4, 219ra9.
[30] D. Bannon, E. Moen, M. Schwartz, E. Borba, T. Kudo, N. Greenwald, V. Vijayakumar, B. Chang, E. Pao, E. Osterman, W. Graf, D. Van Valen, *Nat. Methods* 2021, 18, 43.

[31] N. F. Greenwald, G. Miller, E. Moen, A. Kong, A. Kagel, T. Dougherty, C. C. Fullaway, B. J. McIntosh, K. Leow, M. S. Schwartz, C. Pavelchek, S. Cui, I. Camplisson, O. Bar-Tal, J. Singh, M. Fong, G. Chaudhry, Z. Abraham, J. Moseley, S. Warshawsky, E. Soon, S. Greenbaum, T. Risom, T. Hollmann, S. C. Bendall, L. Keren, W. Graf, M. Angelo, D. Van Valen, *Nat. Biotechnol.* 2021.

[32] C. Stringer, T. Wang, M. Michaelos, M. Pachitariu, *Nat. Methods* 2021, 18, 100.